Lb Pharmaceuticals (LBRX) Accounts Payables (2024 - 2026)

Lb Pharmaceuticals' Accounts Payables history runs 3 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.1 million, down 8.32% from the prior year.
• Accounts Payables improved to $7.1 million in Q1 2026 per LBRX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.1 million in Q1 2026 and bottomed at $2.1 million in Q4 2025.
• The 3-year median for Accounts Payables is $2.5 million (2024), against an average of $3.5 million.
• Biggest YoY gain for Accounts Payables was 8.32% in 2025; the steepest drop was 8.32% in 2025.
• Year by year, Accounts Payables stood at $2.3 million in 2024, then fell by 8.32% to $2.1 million in 2025, then surged by 234.7% to $7.1 million in 2026.
• Per Business Quant, the three latest LBRX Accounts Payables figures stand at $7.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.6 million (Q3 2025).